Dr. Scott D. Lunin, M.D.
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Duke University School of Medicine (1995)
- Years since graduation
- 31
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 878
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1995Medical school: Duke University School of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
FL license ME83359 -
Hematology (Internal Medicine) Physician
FL license ME83359
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Sarasota Memorial Hospital Sarasota, FL
- Sarasota Memorial Hospital - Venice North Venice, FL
Medical groups
- Florida Cancer Specialists and Research Institute, LLC (498 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 878
- Services billed
- 300,973
- Patients’ average age
- 77
| Service | Times | Patients |
|---|---|---|
| Injection, pembrolizumab, 1 mg | 38,000 | 31 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 35,700 | 36 |
| Injection, iron sucrose, 1 mg | 35,700 | 49 |
| Injection, oxaliplatin, 0.5 mg | 24,060 | 15 |
| Injection, aprepitant, 1 mg | 23,530 | 39 |
| Injection, daratumumab, 10 mg and hyaluronidase-fihj | 18,720 | 12 |
| Injection, paclitaxel, 1 mg | 18,555 | 20 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 17,090 | 42 |
| Injection, denosumab, 1 mg | 8,160 | 54 |
| Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | 7,780 | 16 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Anastrozole Other prescribers in Sarasota, FL | 122 |
| Tamoxifen Citrate Other prescribers in Sarasota, FL | 98 |
| Eliquis (apixaban) Other prescribers in Sarasota, FL | 62 |
| Ondansetron Odt (ondansetron) Other prescribers in Sarasota, FL | 56 |
| Prednisone Other prescribers in Sarasota, FL | 53 |
| Letrozole Other prescribers in Sarasota, FL | 52 |
| Ibrance (palbociclib) | 50 |
| Gabapentin Other prescribers in Sarasota, FL | 50 |
| Alprazolam Other prescribers in Sarasota, FL | 49 |
| Hydroxyurea Other prescribers in Sarasota, FL | 49 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 31 companies reported 120 payments worth $2,393 in total to this clinician.
| Janssen Biotech, Inc. | $314 |
|---|---|
| Pfizer Inc. | $196 |
| Merck Sharp & Dohme LLC | $172 |
| Novartis Pharmaceuticals Corporation | $172 |
| Gilead Sciences, Inc. | $140 |
| Celgene Corporation | $136 |
| E.r. Squibb & Sons, L.l.c. | $126 |
| Incyte Corporation | $111 |
| Food and Beverage | $2,393 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 6 companies. The companies reported $432,946 in research payments for these studies, mostly to the institutions running them.
- A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of Zanubrutinib
Beone Medicines Ltd. · Active, not recruiting · NCT04170283 - Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)
Aadi Bioscience, Inc. · Completed · NCT05103358 - A single arm multicenter nilotinib treatment free remission study in patients with BCR ABL1 positive Chronic Myelogenous Leukemia in chronic phase who have achieved durable minimal residual disease MRD status on first…
Novartis Pharmaceuticals Corporation - A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination with Chlorambucil, ACP-196 in Combination with Obinutuzumab, and ACP-196 Monotherapy in Subjects with Previously Untreated Chro…
Acerta Pharma LLC - A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma
Takeda Pharmaceuticals U.S.A., Inc. · Completed · NCT01712490 - A Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy
Janssen Research & Development, LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.